Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: February 2nd, 2010 - February 2nd, 2011

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with non-Hodgkin's lymphoma.

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

  • Describe recent advances in the treatment of newly diagnosed and relapsed/refractory non-Hodgkin’s lymphoma (NHL)
  • Identify the risks and benefits of investigational agents being evaluated for the treatment of NHL
  • Review recent safety and efficacy data as it relates to recently approved therapies for NHL


Agenda - 1.5 hours
• Articles/Commentaries: 75 minutes
• Evaluation/Post-Test: 15 minutes

Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.5 contact hours.

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.15 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-09-052-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner
or Manager
Company Reported Financial
Amanda Glazar, PhD Global Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Nancy Nesser, PharmD, JD MLI Nothing to disclose
Kathryn Gada, MSN MLI Nothing to disclose
Dana Delibovi COEXM Nothing to disclose
Susan Berry COEXM Nothing to disclose

Faculty Disclosures
André Goy, MD, MS is on the speaker's bureau and is a consultant for Allos, Biogen Idec, Celgene, Genentech, and Millennium.

*Amanda Copeland, MSN, RN, CNS, is on the advisory board for Millennium.

*Anas Younes, MD, is on the advisory board and is a consultant for Abbott Oncology, Allos Therapeutics, Amgen, Biogen Idec, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Italfarmaco, Methylgene, Novartis, Pharmion, Sandoz, sanofi-aventis, Seattle Genetics, Syndax, Tiba Oncology, Trubion, and Xencor.

*Sandra Kurtin, RN, MS, AOCN, ANP-C has nothing to disclose.

Nelly G. Adel, PharmD, BCOP, BCPS has nothing to disclose.

*Content will include non-FDA-approved uses.

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Considerations in Lymphoma Ask the Experts: Hodgkin Lymphoma
David J. Straus, MD, Christine Liebertz, RN, CS, MSN, AOCN, Nelly G. Adel, PharmD, BCOP, BCPS
Supplements published on April 21, 2011
Considerations in Non-Hodgkin's Lymphoma: T-Cell Lymphomas
Andrei Shustov, MD, Nora M. Mueller, PharmD, André Goy, MD, MS
Supplements published on December 23, 2009
Considerations in Non-Hodgkin's Lymphoma: Diffuse Large B-Cell Lymphoma
André Goy, MD, MS, Betty M. Chan, PharmD, BCOP, Christine Liebertz, RN, CS, MSN, AOCN
Supplements published on November 6, 2009
Considerations in Non-Hodgkin's Lymphoma: Waldenstrom's Macroglobulinemia
André Goy, MD, MS, Amy Goodrich, RN, MSN, CRNP, Zaven R. Norigian, PharmD, BCOP
Supplements published on October 15, 2009
Considerations in Non-Hodgkin's Lymphoma: Follicular Lymphoma
André Goy, MD, MS, Andrew M. Evens, DO, MSc, Sonja Crandon, RN, BSN, Cindy L. O'Bryant, PharmD, BCOP
Supplements published on September 30, 2009
Considerations in Non-Hodgkin's Lymphoma: Mantle Cell Lymphoma
André Goy, MD, MS, Steven H. Bernstein, MD
Supplements published on August 10, 2009
Considerations in Multiple Myeloma: Health Economics
Sagar Lonial, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Jessica Freels, PharmD, Laureen Kenealy, PharmD, Jacob Kettle, PharmD, Casey Williams, PharmD, BCOP
Supplements published on October 31, 2008
Last modified: March 24, 2014